1888-1889 / 2351
Our experience
Previous treatment
(S and/or RT and/or
CHT)
25%
(0.6%)
(20.1%)
(28.4%)
(18.9%)
(6.6%)
(25.4%)
pT0
pT1
pT2
pT3
pT4a
pT4b
1
34
48
32
11
43
Pathological stage
EER
ERTC
CER
38 (22.5%)
103 (60.9%)
28 (16.6%)
Positive margins 18 (
10.6%
)
3 pT3, 1 pT4a, 14 pT4b
Adjuvant RT 99 (
58.6
%)
Nicolai et al, Head Neck 2015
ADENOCARCINOMA
mercoledì 29 giugno 16